Loss of Acot12 contributes to NAFLD independent of lipolysis of adipose tissue

[1]  N. Chandel,et al.  Mitochondrial TCA cycle metabolites control physiology and disease , 2020, Nature Communications.

[2]  S. Burgess,et al.  Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver. , 2019, JCI insight.

[3]  E. Gratton,et al.  StarD5: an ER stress protein regulates plasma membrane and intracellular cholesterol homeostasis[S] , 2019, Journal of Lipid Research.

[4]  L. Qin,et al.  ACOT12-Dependent Alteration of Acetyl-CoA Drives Hepatocellular Carcinoma Metastasis by Epigenetic Induction of Epithelial-Mesenchymal Transition. , 2019, Cell metabolism.

[5]  G. Shulman,et al.  Acetyl‐CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents , 2018, Hepatology.

[6]  T. Kodama,et al.  Discovery of peroxisome proliferator–activated receptor α (PPARα) activators with a ligand-screening system using a human PPARα-expressing cell line , 2018, The Journal of Biological Chemistry.

[7]  H. Shimano,et al.  SREBP-regulated lipid metabolism: convergent physiology — divergent pathophysiology , 2017, Nature Reviews Endocrinology.

[8]  D. Cohen,et al.  Deactivating Fatty Acids: Acyl-CoA Thioesterase-Mediated Control of Lipid Metabolism , 2017, Trends in Endocrinology & Metabolism.

[9]  G. Drin,et al.  STARD3 mediates endoplasmic reticulum‐to‐endosome cholesterol transport at membrane contact sites , 2017, The EMBO journal.

[10]  D. Vance,et al.  Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase[S] , 2017, Journal of Lipid Research.

[11]  Jun Wu,et al.  Isolation of Mouse Stromal Vascular Cells for Monolayer Culture. , 2017, Methods in molecular biology.

[12]  K. Reiss,et al.  Regulation of Ketone Body Metabolism and the Role of PPARα , 2016, International journal of molecular sciences.

[13]  K. Tsuneyama,et al.  High‐fat and high‐cholesterol diet rapidly induces non‐alcoholic steatohepatitis with advanced fibrosis in Sprague–Dawley rats , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  Philippe Lefebvre,et al.  Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. , 2015, Journal of hepatology.

[15]  M. Trauner,et al.  Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD , 2014, Trends in Endocrinology & Metabolism.

[16]  N. Cowieson,et al.  Structural Basis for Regulation of the Human Acetyl-CoA Thioesterase 12 and Interactions with the Steroidogenic Acute Regulatory Protein-related Lipid Transfer (START) Domain , 2014, The Journal of Biological Chemistry.

[17]  H. Kalbacher,et al.  De novo lipogenesis in health and disease. , 2014, Metabolism: clinical and experimental.

[18]  N. Møller,et al.  Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. , 2014, Journal of molecular endocrinology.

[19]  S. King,et al.  STARD6 is expressed in steroidogenic cells of the ovary and can enhance de novo steroidogenesis , 2014, Experimental biology and medicine.

[20]  S. D. Rider,et al.  Divergence between human and murine peroxisome proliferator-activated receptor alpha ligand specificities[S] , 2013, Journal of Lipid Research.

[21]  M. Itoh,et al.  Enzymatic and transcriptional regulation of the cytoplasmic acetyl-CoA hydrolase ACOT12[S] , 2013, Journal of Lipid Research.

[22]  H. Balderhaar,et al.  CORVET and HOPS tethering complexes – coordinators of endosome and lysosome fusion , 2013, Journal of Cell Science.

[23]  J. Ellis,et al.  Acyl Coenzyme A Thioesterase 7 Regulates Neuronal Fatty Acid Metabolism To Prevent Neurotoxicity , 2013, Molecular and Cellular Biology.

[24]  K. Zatloukal,et al.  Gene Expression Profiling Unravels Cancer-Related Hepatic Molecular Signatures in Steatohepatitis but Not in Steatosis , 2012, PloS one.

[25]  M. Siponen,et al.  The emerging role of acyl-CoA thioesterases and acyltransferases in regulating peroxisomal lipid metabolism. , 2012, Biochimica et biophysica acta.

[26]  A. Sanyal,et al.  Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. , 2012, Cell metabolism.

[27]  K. Cusi,et al.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[28]  P. Larsen,et al.  Targeted deletion of thioesterase superfamily member 1 promotes energy expenditure and protects against obesity and insulin resistance , 2012, Proceedings of the National Academy of Sciences.

[29]  S. Burgess,et al.  Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. , 2011, Cell metabolism.

[30]  Y. Barak,et al.  Role for PPARγ in obesity‐induced hepatic steatosis as determined by hepatocyte‐ and macrophage‐specific conditional knockouts , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  B. Neuschwander‐Tetri.  Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites , 2010, Hepatology.

[32]  Michelle M Wiest,et al.  The plasma lipidomic signature of nonalcoholic steatohepatitis , 2009, Hepatology.

[33]  Puneet Puri,et al.  Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression , 2008, Hepatology.

[34]  Z. Huang,et al.  Activation of peroxisome proliferator-activated receptor-α in mice induces expression of the hepatic low-density lipoprotein receptor , 2008, British journal of pharmacology.

[35]  W. Miller.  Mechanism of StAR's regulation of mitochondrial cholesterol import , 2007, Molecular and Cellular Endocrinology.

[36]  N. Kaplowitz,et al.  Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. , 2006, Journal of hepatology.

[37]  K. Gumireddy,et al.  Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. , 2005, Diabetes.

[38]  G. Gibbons,et al.  A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver. , 2005, The Biochemical journal.

[39]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[40]  J. Schneider,et al.  "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. , 2005, Cell metabolism.

[41]  I. Leclercq,et al.  Administration of the potent PPARα agonist, Wy‐14,643, reverses nutritional fibrosis and steatohepatitis in mice , 2004, Hepatology.

[42]  I. Leclercq,et al.  Central role of PPARα‐dependent hepatic lipid turnover in dietary steatohepatitis in mice , 2003, Hepatology.

[43]  F. Foufelle,et al.  New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. , 2002, The Biochemical journal.

[44]  D. Severson,et al.  A Role for Peroxisome Proliferator-activated Receptor α (PPARα) in the Control of Cardiac Malonyl-CoA Levels , 2002, The Journal of Biological Chemistry.

[45]  S. Colman,et al.  BFIT, a unique acyl-CoA thioesterase induced in thermogenic brown adipose tissue: cloning, organization of the human gene and assessment of a potential link to obesity. , 2001, The Biochemical journal.

[46]  J. Lehmann,et al.  Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.

[47]  G. Gores,et al.  Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.